Pharmacists in Maryville, Missouri


13 Pharmacists found in Maryville
female pharmacist

Angela Lynn Morrison, RPH


Pharmacist
1605 S Main St, Maryville, MO 64468
660-562-3593    

male pharmacist

Anthony Christopher Grainger, PHARM.D.


Pharmacist
1217 S Main St, Maryville, MO 64468
660-582-2199    

female pharmacist

Beth Marie Hornbuckle


Pharmacist
1605 S Main St, Maryville, MO 64468
660-562-3593     660-562-3282



male pharmacist

Dean Melvin Schneider


Pharmacist
1217 S Main St, Maryville, MO 64468
660-582-2199    

male pharmacist

Jamie Edward Barnett


Pharmacist
1605 S Main St, Maryville, MO 64468
660-562-3593     660-562-3282

female pharmacist

Jessica Stiens


Pharmacist
1217 S Main St, Maryville, MO 64468
660-582-2199     660-582-2456

female pharmacist

Julie Simmerman, PHARM D


Pharmacist
125 E South Ave, Maryville, MO 64468
660-562-2300    

female pharmacist

Marah Elizabeth Heckman, PHARMD


Pharmacist
1114 S Main St, Maryville, MO 64468
660-562-2157    

male pharmacist

Nolan A Ritzinger, PHARM.D


Pharmacist
1217 S Main St, Maryville, MO 64468
660-582-2199    

male pharmacist

Mr. Rick Alan Carter, RPH


Pharmacist
125 E South Ave, Maryville, MO 64468
660-562-2300     660-224-0259

male pharmacist

Dr. Shane Mcmillan, PHARMD


Pharmacist
1217 S Main St, Maryville, MO 64468
660-582-2199     660-582-2456

female pharmacist

Mrs. Theresa Ann Rowan, RPH


Pharmacist
1114 S Main St, Maryville, MO 64468
660-562-2157     660-562-2589

male pharmacist

Trenton Stumpff, R.PH.


Pharmacist
125 E South Ave, Maryville, MO 64468
660-562-2300     660-224-0259


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.